Clinical Trial

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a Phase III randomized, double-blind, positive controlled study to evaluate the efficacy, safety, and pharmacokinetics of HMPL-760 in combination with R-GemOx versus placebo in combination with R-GemOx in patients with R/R DLBCL.
Protocol Amendment History 3 changes
notable Trial sites expanded: 41 -> 50 locations 2026-07-21
critical Recruitment opened 2026-04-02
notable Trial sites expanded: 0 -> 41 locations 2026-04-02
Trial Details
NCT Number NCT07409428
Lead Sponsor Hutchmed
Conditions Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Enrollment 240 participants
Start Date 2026-03-20
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-20